6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes

Histopathologic classification of breast neoplasms defines tumor biology, informs prognostic staging, and establishes the foundation for systemic and locoregional treatment algorithms. Breast care nurses must understand tumor morphology, architectural growth patterns, and margin guidelines to effectively translate pathology reports for patients and multidisciplinary teams.

Non-Invasive Breast Carcinomas (Carcinoma In Situ)

In situ carcinomas represent neoplastic proliferations of epithelial cells that remain entirely confined within the basement membrane of the mammary ductal-lobular architecture, lacking the enzymatic capability to invade surrounding vascular or lymphatic stroma.

Ductal Carcinoma In Situ (DCIS)

DCIS represents approximately 20% to 25% of all mammographically detected breast malignancies, classically presenting as asymptomatic clustered pleomorphic or linear microcalcifications:

• Pathophysiology: Clonal proliferation of cytologically malignant epithelial cells that fill and distend breast ducts while respecting the outer basement membrane and myoepithelial cell layer.
• Architectural patterns: Histologically categorized into comedo and non-comedo patterns. The comedo subtype is characterized by central necrosis, high nuclear pleomorphism, and calcifications, representing an aggressive phenotype with a higher propensity for microinvasion. Non-comedo patterns include solid, cribriform (sieve-like fenestrations), papillary, and micropapillary.
• Natural history: Regarded as a non-obligate precursor to invasive ductal carcinoma. Untreated DCIS progresses to invasive carcinoma in an estimated 20% to 50% of cases over a 10- to 15-year period.
• Surgical margin standard: The Society of Surgical Oncology (SSO) and American Society for Radiation Oncology (ASTRO) consensus guidelines establish a minimum 2 mm clear negative surgical margin as the standard of care for DCIS treated with breast-conserving surgery and whole-breast radiation therapy. Margins less than 2 mm are associated with increased local recurrence and typically warrant re-excision.

Lobular Carcinoma In Situ (LCIS)

LCIS originates within the terminal duct lobular unit (TDLU) and is typically an incidental finding on core biopsy performed for unrelated imaging abnormalities:

• Molecular hallmark: Complete biallelic loss of E-cadherin expression (encoded by the CDH1 gene), a transmembrane glycoprotein responsible for calcium-dependent intercellular adhesion. Its absence causes discohesive, monomorphic, round cells that loosely fill and distend lobular acini.
• Clinical significance of classic LCIS: Classic LCIS is not considered a direct anatomic precursor to invasive cancer, but rather a non-obligate bilateral risk marker. It confers an approximate 1% to 2% annual risk (20% to 30% lifetime risk) of developing invasive breast cancer in either breast. Approximately two-thirds of subsequent invasive cancers are invasive ductal carcinomas rather than invasive lobular carcinomas.
• Pleomorphic LCIS (PLCIS): A distinct, aggressive variant characterized by marked nuclear pleomorphism, signet ring cells, comedo-type necrosis, and elevated Ki-67 proliferation index. Unlike classic LCIS, pleomorphic LCIS behaves biologically like high-grade DCIS and requires complete surgical excision with negative margins.

Invasive Breast Carcinoma Major Subtypes

Invasive carcinoma occurs when malignant cells breach the basement membrane and infiltrate the surrounding stroma, gaining access to blood vessels and lymphatic channels.

Invasive Ductal Carcinoma (IDC / Invasive Carcinoma of No Special Type)

Invasive ductal carcinoma (IDC), officially designated by the World Health Organization (WHO) as Invasive Carcinoma of No Special Type (NST), constitutes approximately 70% to 80% of all invasive breast cancers:

• Histologic grading: Graded using the Nottingham Modification of the Bloom-Richardson system, which evaluates three morphologic features, each scored from 1 to 3 points:
  1. Tubule and glandular formation: More than 75% of tumor forming tubules (1 point), 10% to 75% (2 points), less than 10% (3 points).
  2. Nuclear pleomorphism: Small, uniform cells (1 point), moderate variation in size and shape (2 points), marked pleomorphism with vesicular chromatin and prominent nucleoli (3 points).
  3. Mitotic count: Scored 1 to 3 points based on the number of mitotic figures identified per 10 high-power fields (HPF).
  • Combined score: Grade 1 (Well-differentiated, score 3-5); Grade 2 (Moderately differentiated, score 6-7); Grade 3 (Poorly differentiated, score 8-9).

Invasive Lobular Carcinoma (ILC)

Invasive lobular carcinoma represents the second most common histologic subtype, accounting for 10% to 15% of all invasive breast malignancies:

• Histologic hallmark: Characterized by the complete loss of E-cadherin expression, resulting in small, discohesive tumor cells that infiltrate the stroma in a linear, single-file pattern. The cells permeate between collagen fibers and encircle pre-existing normal mammary ducts in concentric targetoid rings without eliciting a vigorous host desmoplastic reaction.
• Diagnostic challenges: Due to the lack of desmoplasia, ILC frequently presents as an indistinct, vague palpable fullness rather than a discrete hard mass, and is notoriously difficult to detect on screening mammography, often appearing as subtle architectural distortion or remaining entirely mammographically occult.
• Clinical presentation: Demonstrates significantly higher frequencies of bilateral breast involvement (10% to 20%) and multicentric or multifocal disease compared to IDC.
• Metastatic patterns: Exhibits a distinct, atypical pattern of distant metastasis compared to IDC. While IDC preferentially disseminates to the lungs, liver, bones, and brain, ILC displays unique tropism for serosal surfaces, including the peritoneum, retroperitoneum, gastrointestinal tract (stomach and colon mimicking primary linitis plastica), ovaries, uterus, and leptomeninges.

Special Histological Subtypes of Breast Carcinoma

Approximately 10% of breast carcinomas display unique histological characteristics with distinctive clinical behaviors:

Tubular Carcinoma

Comprising 1% to 2% of invasive breast cancers, tubular carcinoma consists of well-differentiated, regular oval-to-round tubules lined by a single layer of low-grade epithelial cells with apical snouts and absent myoepithelial cells:

• Prognosis: Exceptional overall prognosis with very low axillary nodal involvement (less than 5% to 10%).
• Biomarker profile: Almost uniformly strongly estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), and HER2-negative.

Mucinous (Colloid) Carcinoma

Accounting for 2% of invasive tumors, pure mucinous carcinoma is characterized by islands and clusters of uniform, low-grade malignant epithelial cells floating within abundant pools of extracellular mucin:

• Clinical features: Most common in postmenopausal women. Pure mucinous carcinoma has an indolent clinical course, low rate of regional nodal metastases, and favorable long-term disease-specific survival.

Carcinoma With Medullary Pattern (Formerly Medullary Carcinoma)

Characterized by a well-circumscribed, syncytial growth pattern of high-grade pleomorphic cells, prominent lymphoplasmacytic stromal infiltrate, and lack of tubular architecture:

• Clinical paradox: Despite high histologic grade and a triple-negative (ER-/PR-/HER2-) receptor phenotype, tumors with medullary features demonstrate a paradoxically favorable prognosis with lower-than-expected rates of distant recurrence. Frequently associated with germline BRCA1 mutations. The WHO 5th edition (2019) no longer recognizes medullary carcinoma as a separate type; these tumors are classified as invasive carcinoma of no special type with a medullary pattern, a tumor-infiltrating lymphocyte-rich phenotype.

Metaplastic Breast Carcinoma (MBC)

A rare (less than 1%), aggressive subtype characterized by a mixture of malignant epithelial adenocarcinoma components with heterologous mesenchymal elements (spindle cell, squamous, chondroid, or osteoid differentiation):

• Clinical behavior: Typically presents as a rapidly growing, large, palpable mass. Predominantly triple-negative, chemoresistant to standard anthracycline/taxane regimens, and exhibits a high rate of early hematogenous dissemination (particularly to the lungs) with poor overall prognosis.

Paget Disease of the Nipple

Characterized by the presence of large, intraepithelial malignant adenocarcinoma cells (Paget cells) featuring pale, vacuolated cytoplasm and prominent nucleoli within the epidermis of the nipple and areolar complex:

• Clinical presentation: Presents as unilateral erythema, scaling, eczematous crusting, pruritus, or erosion of the nipple. Over 90% to 95% of cases have an underlying ductal carcinoma in situ or invasive ductal carcinoma within the lactiferous ducts.

Inflammatory Breast Cancer (IBC)

Representing 1% to 5% of all breast cancers, IBC is the most aggressive primary breast malignancy:

• Pathophysiology: Defined pathologically by tumor emboli infiltrating and obstructing dermal lymphatic vessels, although dermal lymphatic invasion on punch biopsy is not strictly mandatory if classic clinical criteria are met.
• Clinical hallmarks: Rapid onset (within 6 months) of diffuse erythema, warmth, induration, and peau d'orange edema involving at least one-third of the breast, often without a discrete palpable mass. Staged as cT4d (Stage IIIB, IIIC, or IV depending on nodal and distant spread).
• Multimodal management: Managed aggressively with neoadjuvant systemic chemotherapy, followed by modified radical mastectomy (breast conservation is contraindicated) and post-mastectomy comprehensive chest wall/nodal radiation.

Other Prognostic Features on the Pathology Report

The CBCN outline lists prognostic features beyond histologic type and grade. Nurses should be able to explain each one:

Pathology reports follow the College of American Pathologists (CAP) synoptic protocol, so histologic type, grade, size, margins, LVI, lymph node findings, ENE, and biomarkers appear in a consistent order. Walking a patient through that template is a practical nursing skill.

Histopathologic Subtypes Comparison

Nursing Considerations in Pathology Interpretation

Nurses assist patients in understanding their pathology reports by:

• Distinguishing Grade from Stage: Clarifying that histologic grade describes cellular differentiation and aggressiveness under the microscope, whereas stage reflects anatomical tumor size, nodal involvement, and distant spread.
• Educating on LCIS vs. DCIS: Reassuring patients with classic LCIS that their condition is a risk marker for both breasts rather than a malignant cancer invading breast tissue, while explaining endocrine risk reduction options.
• Vigilance for ILC metastatic patterns: Educating patients treated for ILC to report subtle gastrointestinal symptoms (early satiety, abdominal distension, bowel habit changes) given the atypical peritoneal and GI metastatic tropism of lobular carcinoma.